Cargando…

Predicting Re-Exacerbation Timing and Understanding Prolonged Exacerbations: An Analysis of Patients with COPD in the ECLIPSE Cohort

PURPOSE: Understanding risk factors for an acute exacerbation of chronic obstructive pulmonary disease (AECOPD) is important for optimizing patient care. We re-analyzed data from the Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) study (NCT00292552) to identif...

Descripción completa

Detalles Bibliográficos
Autores principales: Meeraus, Wilhelmine H, Mullerova, Hana, El Baou, Céline, Fahey, Marion, Hessel, Edith M, Fahy, William A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7872897/
https://www.ncbi.nlm.nih.gov/pubmed/33574663
http://dx.doi.org/10.2147/COPD.S279315
_version_ 1783649279327338496
author Meeraus, Wilhelmine H
Mullerova, Hana
El Baou, Céline
Fahey, Marion
Hessel, Edith M
Fahy, William A
author_facet Meeraus, Wilhelmine H
Mullerova, Hana
El Baou, Céline
Fahey, Marion
Hessel, Edith M
Fahy, William A
author_sort Meeraus, Wilhelmine H
collection PubMed
description PURPOSE: Understanding risk factors for an acute exacerbation of chronic obstructive pulmonary disease (AECOPD) is important for optimizing patient care. We re-analyzed data from the Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) study (NCT00292552) to identify factors predictive of re-exacerbations and associated with prolonged AECOPDs. METHODS: Patients with COPD from ECLIPSE with moderate/severe AECOPDs were included. The end of the first exacerbation was the index date. Timing of re-exacerbation risk was assessed in patients with 180 days’ post-index-date follow-up data. Factors predictive of early (1–90 days) vs late (91–180 days) vs no re-exacerbation were identified using a multivariable partial-proportional-odds-predictive model. Explanatory logistic-regression modeling identified factors associated with prolonged AECOPDs. RESULTS: Of the 1,554 eligible patients from ECLIPSE, 1,420 had 180 days’ follow-up data: more patients experienced early (30.9%) than late (18.7%) re-exacerbations; 50.4% had no re-exacerbation within 180 days. Lower post-bronchodilator FEV(1) (P=0.0019), a higher number of moderate/severe exacerbations on/before index date (P<0.0001), higher St. George’s Respiratory Questionnaire total score (P=0.0036), and season of index exacerbation (autumn vs winter, P=0.00164) were identified as predictors of early (vs late/none) re-exacerbation risk within 180 days. Similarly, these were all predictors of any (vs none) re-exacerbation risk within 180 days. Median moderate/severe AECOPD duration was 12 days; 22.7% of patients experienced a prolonged AECOPD. The odds of experiencing a prolonged AECOPD were greater for severe vs moderate AECOPDs (adjusted odds ratio=1.917, P=0.002) and lower for spring vs winter AECOPDs (adjusted odds ratio=0.578, P=0.017). CONCLUSION: Prior exacerbation history, reduced lung function, poorer respiratory-related quality-of-life (greater disease burden), and season may help identify patients who will re-exacerbate within 90 days of an AECOPD. Severe AECOPDs and winter AECOPDs are likely to be prolonged and may require close monitoring.
format Online
Article
Text
id pubmed-7872897
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-78728972021-02-10 Predicting Re-Exacerbation Timing and Understanding Prolonged Exacerbations: An Analysis of Patients with COPD in the ECLIPSE Cohort Meeraus, Wilhelmine H Mullerova, Hana El Baou, Céline Fahey, Marion Hessel, Edith M Fahy, William A Int J Chron Obstruct Pulmon Dis Original Research PURPOSE: Understanding risk factors for an acute exacerbation of chronic obstructive pulmonary disease (AECOPD) is important for optimizing patient care. We re-analyzed data from the Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) study (NCT00292552) to identify factors predictive of re-exacerbations and associated with prolonged AECOPDs. METHODS: Patients with COPD from ECLIPSE with moderate/severe AECOPDs were included. The end of the first exacerbation was the index date. Timing of re-exacerbation risk was assessed in patients with 180 days’ post-index-date follow-up data. Factors predictive of early (1–90 days) vs late (91–180 days) vs no re-exacerbation were identified using a multivariable partial-proportional-odds-predictive model. Explanatory logistic-regression modeling identified factors associated with prolonged AECOPDs. RESULTS: Of the 1,554 eligible patients from ECLIPSE, 1,420 had 180 days’ follow-up data: more patients experienced early (30.9%) than late (18.7%) re-exacerbations; 50.4% had no re-exacerbation within 180 days. Lower post-bronchodilator FEV(1) (P=0.0019), a higher number of moderate/severe exacerbations on/before index date (P<0.0001), higher St. George’s Respiratory Questionnaire total score (P=0.0036), and season of index exacerbation (autumn vs winter, P=0.00164) were identified as predictors of early (vs late/none) re-exacerbation risk within 180 days. Similarly, these were all predictors of any (vs none) re-exacerbation risk within 180 days. Median moderate/severe AECOPD duration was 12 days; 22.7% of patients experienced a prolonged AECOPD. The odds of experiencing a prolonged AECOPD were greater for severe vs moderate AECOPDs (adjusted odds ratio=1.917, P=0.002) and lower for spring vs winter AECOPDs (adjusted odds ratio=0.578, P=0.017). CONCLUSION: Prior exacerbation history, reduced lung function, poorer respiratory-related quality-of-life (greater disease burden), and season may help identify patients who will re-exacerbate within 90 days of an AECOPD. Severe AECOPDs and winter AECOPDs are likely to be prolonged and may require close monitoring. Dove 2021-02-05 /pmc/articles/PMC7872897/ /pubmed/33574663 http://dx.doi.org/10.2147/COPD.S279315 Text en © 2021 Meeraus et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Meeraus, Wilhelmine H
Mullerova, Hana
El Baou, Céline
Fahey, Marion
Hessel, Edith M
Fahy, William A
Predicting Re-Exacerbation Timing and Understanding Prolonged Exacerbations: An Analysis of Patients with COPD in the ECLIPSE Cohort
title Predicting Re-Exacerbation Timing and Understanding Prolonged Exacerbations: An Analysis of Patients with COPD in the ECLIPSE Cohort
title_full Predicting Re-Exacerbation Timing and Understanding Prolonged Exacerbations: An Analysis of Patients with COPD in the ECLIPSE Cohort
title_fullStr Predicting Re-Exacerbation Timing and Understanding Prolonged Exacerbations: An Analysis of Patients with COPD in the ECLIPSE Cohort
title_full_unstemmed Predicting Re-Exacerbation Timing and Understanding Prolonged Exacerbations: An Analysis of Patients with COPD in the ECLIPSE Cohort
title_short Predicting Re-Exacerbation Timing and Understanding Prolonged Exacerbations: An Analysis of Patients with COPD in the ECLIPSE Cohort
title_sort predicting re-exacerbation timing and understanding prolonged exacerbations: an analysis of patients with copd in the eclipse cohort
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7872897/
https://www.ncbi.nlm.nih.gov/pubmed/33574663
http://dx.doi.org/10.2147/COPD.S279315
work_keys_str_mv AT meerauswilhelmineh predictingreexacerbationtimingandunderstandingprolongedexacerbationsananalysisofpatientswithcopdintheeclipsecohort
AT mullerovahana predictingreexacerbationtimingandunderstandingprolongedexacerbationsananalysisofpatientswithcopdintheeclipsecohort
AT elbaouceline predictingreexacerbationtimingandunderstandingprolongedexacerbationsananalysisofpatientswithcopdintheeclipsecohort
AT faheymarion predictingreexacerbationtimingandunderstandingprolongedexacerbationsananalysisofpatientswithcopdintheeclipsecohort
AT hesseledithm predictingreexacerbationtimingandunderstandingprolongedexacerbationsananalysisofpatientswithcopdintheeclipsecohort
AT fahywilliama predictingreexacerbationtimingandunderstandingprolongedexacerbationsananalysisofpatientswithcopdintheeclipsecohort